Meclizine Hydrochloride
FDA-approved product (tablet, chewable, oral), marketed as Antivert, Meclizine Hydrochloride.
- Registered studies
- 11
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Allergic disease
- Motion sickness
- Nausea
- Nausea and vomiting
- Vertigo
- Vomiting
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Piperazine derivatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA44.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli40.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae16.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
11registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Meclizine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers
NCT07681076 · start 2026-09-03
Registered record
- Registry ID
- NCT07681076
- Conditions
- Healthy Volunteers
- Interventions
- KarXT; Trimethobenzamide; Ondansetron; Meclizine
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Recruiting
- Start
- 2026-09-03
- Completion
- 2026-11-30
- Enrolment
- 225
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteersInterventionKarXT; Trimethobenzamide; Ondansetron; MeclizinePhasePhase 4Registry statusRecruitingCombination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
NCT05852730 · start 2021-08-10
Registered record
- Registry ID
- NCT05852730
- Conditions
- Motion Sickness, Space; Motion Simulation; Parabolic Flight
- Interventions
- DPI-386 Nasal Gel; Other (e.g., promethazine, meclizine)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2021-08-10
- Completion
- 2026-09
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMotion Sickness, Space; Motion Simulation; Parabolic FlightInterventionDPI-386 Nasal Gel; Other (e.g., promethazine, meclizine)PhasePhase 2Registry statusRecruitingMeclizine Plasma Levels in Responders and Non-responders
NCT04482985 · start 2020-09-01
Registered record
- Registry ID
- NCT04482985
- Conditions
- Seasickness; Meclizine
- Interventions
- Meclizine Hydrochloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2020-09-01
- Completion
- 2021-09-01
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSeasickness; MeclizineInterventionMeclizine HydrochloridePhasePhase 4Registry statusUnknownEvaluation of Meclizine Orodispersible Tablet Pharmacokinetic in Human Volunteers
NCT04564144 · start 2020-06-01
Registered record
- Registry ID
- NCT04564144
- Conditions
- Emesis
- Interventions
- Meclizine Hydrochloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Unknown
- Start
- 2020-06-01
- Completion
- 2020-12-01
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEmesisInterventionMeclizine HydrochloridePhasePhase 1 / Phase 2Registry statusUnknownMeclizine for Hepatocellular Carcinoma
NCT03253289 · start 2017-10-13
Registered record
- Registry ID
- NCT03253289
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Meclizine Oral Tablet
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2017-10-13
- Completion
- 2023-03-28
- Enrolment
- 13
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCarcinoma, HepatocellularInterventionMeclizine Oral TabletPhasePhase 1Registry statusCompletedMotion Sickness Medications and Vestibular Time Constant
NCT03270839 · start 2017-06-01
Registered record
- Registry ID
- NCT03270839
- Conditions
- Drug Reaction
- Interventions
- Bonine 25Mg Chewable Tablet; Kwells; Placebo Oral Tablet
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2017-06-01
- Completion
- 2020-01-01
- Enrolment
- 54
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDrug ReactionInterventionBonine 25Mg Chewable Tablet; Kwells; Placebo Oral TabletPhasePhase 4Registry statusCompletedNon Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin
NCT02112578 · start 2016-11-01
Registered record
- Registry ID
- NCT02112578
- Conditions
- Vertigo, Peripheral
- Interventions
- Meclizine; Dimenhydrinate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2016-11-01
- Completion
- 2017-12-01
- Enrolment
- 292
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVertigo, PeripheralInterventionMeclizine; DimenhydrinatePhasePhase 3Registry statusCompletedReal-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis
NCT02625181 · start 2016-07
Registered record
- Registry ID
- NCT02625181
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- Automated recommendation at the start of the case; Automated notification at the start of surgery; Preoperative recommendations: by email; Automated notification at the end of surgery; Anesthesia Information Management System (AIMS); Perioperative Data Warehouse (PDW); General anesthesia; Elective surgery; Propofol; Sevoflurane; Isoflurane; Desflurane; Scopolamine; Droperidol; Haloperidol; Dexamethasone; Promethazine; Meclizine; Aprepitant; Metoclopramide; Fentanyl; Sufentanil; Alfentanil; Remifentanil; Morphine; Meperidine; Hydromorphone; Methadone; Oxycodone; Oxymorphone; Hydrocodone; Ketamine; Ondansetron; Granisetron; Dolasetron mesylate; Palonosetron; Tropisetron; Ramosetron
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2016-07
- Completion
- 2017-11-30
- Enrolment
- 27,034
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostoperative Nausea and VomitingInterventionAutomated recommendation at the start of the case; Automated notification at the start of surgery; Preoperative recommendations: by email; Automated notification at the end of surgery +34 morePhaseNot applicableRegistry statusCompletedThe Effects of Antihistamines on Pre-Pulse Inhibition
NCT01537471 · start 2012-01
Registered record
- Registry ID
- NCT01537471
- Conditions
- Healthy
- Interventions
- Placebo; Meclizine; Meclizine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-01
- Completion
- 2012-09
- Enrolment
- 117
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionPlacebo; Meclizine; MeclizinePhasePhase 1Registry statusCompletedMeclizine as a Potential Smoking Cessation Treatment
NCT01443858 · start 2011-08
Registered record
- Registry ID
- NCT01443858
- Conditions
- Smoking Cessation
- Interventions
- Meclizine; Nicotine Patch; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2011-08
- Completion
- 2013-07
- Enrolment
- 146
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSmoking CessationInterventionMeclizine; Nicotine Patch; PlaceboPhasePhase 2Registry statusCompletedTreating Benign Paroxysmal Positional Vertigo (BPPV) in ED Patients
NCT00641797 · start 2006-11
Registered record
- Registry ID
- NCT00641797
- Conditions
- Benign Paroxysmal Positional Vertigo
- Interventions
- Meclizine; Epley Maneuver; Lorazepam; Diphenhydramine; Ondansetron
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2006-11
- Completion
- 2013-11
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Paroxysmal Positional VertigoInterventionMeclizine; Epley Maneuver; Lorazepam; Diphenhydramine +1 morePhaseNot applicableRegistry statusCompleted